A pooled analysis of individual patient data from the major bivalirudin versus unfractionated heparin trials concludes that preprocedural bivalirudin could be considered the agent of choice in the ...
Purpose. The performance of a weight-based dosing protocol for unfractionated heparin (UFH) infusions using antifactor Xa monitoring was evaluated. Methods. The first 50 patients to receive a UFH ...
A new study has shown that COVID-19 patients admitted to the Intensive care unit may be resistant to the naturally occurring anticoagulant Heparin. The study titled, “Heparin resistance in COVID‑19 ...
News Medical: Full intensity heparin has value in treating hospitalized COVID-19 patients
The New England Journal of Medicine: Therapeutic Anticoagulation with Heparin in Patients with Covid-19
EurekAlert!: Bivalirudin found to be safer and more effective than heparin for treating heart attack patients undergoing percutaneous coronary intervention
Bivalirudin is a safer and more effective anticoagulant than heparin for treating patients with the most serious type of heart attacks who undergo urgent percutaneous coronary intervention (PCI), and ...
Bivalirudin found to be safer and more effective than heparin for treating heart attack patients undergoing percutaneous coronary intervention
The New England Journal of Medicine: Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19
Medscape: Achievement of Anticoagulation by Using a Weight-based Heparin Dosing Protocol for Obese and Nonobese Patients
In 1988, Wheeler et al. [8] reported that physicians treating patients for pulmonary embolism and deep-vein thrombosis frequently underdosed their patients and were slow to change their heparin ...
Achievement of Anticoagulation by Using a Weight-based Heparin Dosing Protocol for Obese and Nonobese Patients